nach oben

Breast Cancer Research

Erschienen in:

01.12.2009 | Short communication

Foundation clinical trials

verfasst von: David Cameron

Erschienen in: Breast Cancer Research | Sonderheft 3/2009

Einloggen, um Zugang zu erhalten

Excerpt

The present talk will address the following questions, posed as part of the 2009 Breast Cancer Controversies Meeting: Are clinical trials still essential to develop the new generation of biological agents? Are the traditional large clinical trials appropriate in developing drugs that may have a target in a minority of breast cancers? Are clinical trials compatible with the aim of individualising treatments? …

Olivotto IA, Bajdik CD, Plenderleith IH, Coppin CM, Gelmon KA, Jackson SM, Ragaz J, Wilson KS, Worth A: Adjuvant systemic therapy and survival after breast cancer [see comment]. N Engl J Med. 1994, 330: 805-810. 10.1056/NEJM199403243301201.CrossRefPubMed

Andre F, Slimane K, Bachelot T, Dunant T, Namer M, Barrelier A, Kabbaj O, Spano J-P, Marsiglia H, Rouzier R, Delalogue S, Spielman M: Breast cancer with synchronous metastases: trends in survival during a 14 year period. J Clin Oncol. 2004, 22: 3302-3308. 10.1200/JCO.2004.08.095.CrossRefPubMed

Allred DC, Harvey JM, Berardo MD, Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998, 11: 155-168.PubMed

Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 [see comment]. N Engl J Med. 2001, 344: 783-792. 10.1056/NEJM200103153441101.CrossRefPubMed

Smith IE: Efficacy and safety of Herceptin in women with metastatic breast cancer: results from pivotal clinical studies. Anti-Cancer Drugs. 2001, 12 (Suppl 4): S3-S10.CrossRefPubMed

Thomlinson RH: Measurement and management of carcinoma of the breast. Clin Radiol. 1982, 33: 481-493. 10.1016/S0009-9260(82)80153-0.CrossRefPubMed

Titel: Foundation clinical trials
verfasst von: David Cameron
Publikationsdatum: 01.12.2009
Verlag: BioMed Central
Erschienen in: Breast Cancer Research / Ausgabe Sonderheft 3/2009
Elektronische ISSN: 1465-542X
DOI: https://doi.org/10.1186/bcr2442

Neu im Fachgebiet Onkologie

16.04.2024 | Maligne primäre ZNS-Tumoren | Nachrichten

Springer Medizin

Foundation clinical trials

Excerpt

Neu im Fachgebiet Onkologie

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Das Ende der vollständigen axillären Lymphknotendissektion

Update Onkologie

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 3/2009

Do BIG1-98 and ZOFAST demand a change in guidelines for endocrine therapy?

Gene expression profiling of breast cancer

The potential of new technologies/approaches. Introduction to Sessions 3 and 4

Are current drug development programmes realising the full potential of new agents? Introduction to Sessions 7 and 8

The role of preclinical animal models in breast cancer drug development

Are current drug development programmes realising the full potential of new agents? Tyrosine kinase inhibitors

Neu im Fachgebiet Onkologie

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Das Ende der vollständigen axillären Lymphknotendissektion

Update Onkologie